Skip to main content
Ari Vanderwalde, MD, Oncology, Memphis, TN

AriM.VanderwaldeMDMPH, MBioeth, FACP

Oncology • Memphis, TN

Melanoma, Clinical Informatics

Vice President, Clinical Development, Precision Oncology Alliance, Caris Life Sciences/ Research Faculty, West Cancer Center

Join to view full profile

Dr. Vanderwalde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Vanderwalde's full profile

Already have an account?

Summary

  • Dr. Ari Vanderwalde is an oncologist working as the Vice President of Clinical Development for the Precision Oncology Alliance with Caris Life Sciences. He also works as Research Faculty at West Cancer Center in Memphis, TN where he served as the Director of Research from 2014 to 2021. He was the Medical Director for Precision Oncology for One Oncology from 2020-21 and was Associate Vice Chancellor for Clinical Research at University of Tennessee Health Science Center from 2014-2020. He is Senior Medical Director of George Clinical, and a Professor at the University of Memphis School of Public Health. He is affiliated with multiple hospitals in the area, including St. Jude, Baptist Memorial Hospital - Memphis, Methodist Healthcare Memphis Hospitals. He completed his training in Internal Medicine at UCLA and his fellowship in Hematology/Oncology at City of Hope Cancer Center. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania, his Masters of Public Health from Harvard University, a Masters in Bioethics from Penn, his BA from Harvard, and has been in practice since 2011. He specializes in melanoma and is experienced in genomic tumor assessment, public health, tumor immunotherapy, medical ethics, and precision oncology.

Education & Training

  • City of Hope National Medical Center
    City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • Los Angeles County-Harbor-UCLA Medical Center 1
    Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2008 - 2011
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2005 - 2008
  • Harvard School of Public Health
    Harvard School of Public HealthMPH, Health Care Management, 2003 - 2005
  • University of Pennsylvania
    University of PennsylvaniaMBioethics, 2001 - 2005
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2005, MD, History of Medicine Award, Russell Stumacher Award
  • Harvard University
    Harvard UniversityAB, Biology, Cum laude, 1996 - 2000

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2014 - 2025
  • MS State Medical License
    MS State Medical License 2015 - 2022
  • CA State Medical License
    CA State Medical License 2006 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma  
    Daniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research

Press Mentions

  • Rare but Important Gene Target Found in Many Tumor Types, Suggesting New Therapy Possible
    Rare but Important Gene Target Found in Many Tumor Types, Suggesting New Therapy PossibleApril 15th, 2019
  • Secondary Malignancies: Who Is at Risk and Why?
    Secondary Malignancies: Who Is at Risk and Why?April 19th, 2017

Professional Memberships

Industry Relationships

  • Vice President, Clinical Development, POA, Caris Life SciencesDisclosure: Employment2021 - Present
  • Medical Director, AmgenServed as Medical Director and United States Medical Lead for T-VEC in Global Oncology Development2011 - 2014

Dr. Ari Vanderwalde, Dr. Ari Vanderwalde, MD, Dr. A Vanderwalde, Dr. Ari M. Vanderwalde